Ectopic Pregnancy Clinical Trial
Official title:
Pregnancies of Uncertain Location or Viability Research
Study to determine the diagnostic accuracy of the double decidual sac sign to predict an intrauterine pregnancy prior to ultrasonographic visualisation of embryonic contents using modern ultrasound technology.
This diagnostic accuracy study will be conducted following the standards for reporting of
diagnostic accuracy study (STARD) guidelines. Participants will be recruited from Nurture
Fertility, Nottingham, United Kingdom at the time of embryo transfer. If the subsequent
pregnancy test is positive, participants will be invited to attend for an additional
transvaginal ultrasound scan at 33-34 days gestation. This scan will be considered to be the
'index test'.
The index test will be performed by a single investigator with experience in early pregnancy
ultrasound following standard operating procedures using a Voluson E8 machine with a high
frequency (5-9MHz and 9-12MHz) transvaginal probe. During the early scan the presence or
absence of the following structures will be recorded: an intrauterine fluid collection
(defined as a uniformly round, hypoechoic structure with an echogenic rim); the double
decidual sac sign (DDSS) (defined as two concentric echogenic rings of tissue that surround
the intraendometrial fluid collection that impress upon the endometrial stripe); yolk sac
(defined as a spherical, hyperechoic ring situated eccentrically within the gestation sac);
and fetal pole (defined as a small linear echogenic structure adjacent to the yolk sac, on
the side closest to the gestational sac). If more than one intrauterine fluid collection is
visualized then each will be considered as a separate entity. The findings from the early
scan will be interpreted immediately and recorded separate to the main clinical notes.
Participants will be excluded further from the study if at this point no intrauterine fluid
collection is detected or if an intrauterine fluid collection containing a yolk sac or fetal
pole is identified. Referral pathways to local Early Pregnancy Assessment Units (EPAU) will
be in place for any woman in whom this early scan is strongly suggestive of an ectopic
pregnancy, for example if there was an empty endometrial cavity and either an inhomogenous
adnexal mass or an empty extra-uterine sac or a yolk sac or fetal pole with or without
cardiac activity in an extra-uterine sac.
All women will then have a routine viability ultrasound scan at between 6 and 7 weeks
gestation as per the fertility unit's standard practice. This viability scan was performed
by an appropriately trained doctor or nurse following standard operating procedures and
using the same ultrasound equipment as the index test. This viability scan plus any
subsequent clinical follow-up required i.e. if the diagnosis was not certain following the
viability scan alone, will constituted the reference standard. Clinical follow-up will
consist of a repeat transvaginal ultrasound (TVS) 7-10 days after the initial viability scan
in cases of pregnancies of uncertain viability (defined as the presence of an intrauterine
gestation sac of less than 25mm mean diameter with no obvious yolk sac or fetal pole or an
intrauterine gestation sac containing a fetal pole of less than 7mm with no obvious fetal
heart pulsations) and in cases of pregnancies of uncertain location (defined as no evidence
of an intra- or extra-uterine pregnancy or retained products of conception on transvaginal
ultrasound scan in the presence of a positive urinary pregnancy test), referral to a local
EPAU for monitoring of serial serum human chorionic gonadotropin (β-hCG) levels and
subsequent ultrasonography and possibly surgery where indicated according to departmental
protocols until a definitive diagnosis can be made. Interpretation of the reference standard
will be performed by an experienced gynaecologist without knowledge of the findings from the
index test. Any uncertainty regarding the final diagnosis will be dealt with by seeking the
opinion of two other senior gynaecologists and gaining a consensus opinion.
The outcomes of interest are an intrauterine pregnancy (which may be viable or non-viable)
or an ectopic pregnancy. A viable intrauterine pregnancy is defined as ultrasonographic
identification of an intrauterine gestation sac with a fetal pole of any length with
demonstrable fetal heart pulsations. A non-viable intrauterine pregnancy is defined as
either an empty intrauterine gestation sac with mean sac diameter greater than 25mm or an
intrauterine gestation sac containing a fetal pole with crown rump length greater than 7mm
with no demonstrable fetal heart pulsations or in the absence of a viable embryo, no
significant increase in the growth of the gestation sac or length of the fetal pole on two
ultrasound scans performed more than 7 days apart. Where women undergo surgical or medical
management of miscarriage, histological confirmation of the products of conception will be
obtained when possible. Ectopic pregnancies will be confirmed either by direct visualisation
during surgery with histological confirmation, or, in those managed medically with
methotrexate or conservatively, unequivocal identification of an ectopic pregnancy on
ultrasound scan. Ultrasonographic appearances indicative of an ectopic pregnancy will
include: an empty endometrial cavity with either an inhomogenous adnexal mass or an empty
extra-uterine sac or a yolk sac or fetal pole with or without cardiac activity in an
extra-uterine sac. Following the reference standard, any pregnancy which does not fall into
one of these categories will be excluded from the study. These included resolving or
persisting pregnancies of unknown location.
The sensitivity and specificity of the DDSS for predicting an intrauterine pregnancy (IUP)
will be estimated following cross tabulation of the index test results against those of the
reference standard. The overall diagnostic accuracy, as well as positive and negative
likelihood ratios and predictive values, will also be calculated. Results will be expressed
as percentages for ease of interpretation and 95% confidence intervals will also be given.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02995356 -
Evaluation of the Axonemal Dynein Heavy Chain 5 and Creatine Kinase Concentration in Cervical Fluid for Early Detection of the Ectopic Pregnancy
|
||
Completed |
NCT01876004 -
Effectiveness Of Expectant Management In The Tubal Ectopic Pregnancy
|
Phase 4 | |
Not yet recruiting |
NCT05039853 -
Improving Mental Health Following Early PREgnancy Loss Using a Brief Cognitive Task
|
N/A | |
Completed |
NCT00194207 -
Risk Factors of Ectopic Pregnancy
|
N/A | |
Completed |
NCT00827970 -
Randomized Population-Based Study on Chlamydia Trachomatis Screening
|
N/A | |
Recruiting |
NCT05374720 -
Analysis of the Molecular Composition of Tubal Cilia in Patients With or Without Ectopic Pregnancy
|
N/A | |
Completed |
NCT03894735 -
Vitamin D in Ectopic Pregnancies
|
||
Recruiting |
NCT01860690 -
BHCG Level in Day 4,7, in Comparison to Day 10 as an Indicator for Treatment Success
|
Phase 4 | |
Recruiting |
NCT04176549 -
Assessment of Biomarkers in Ectopic Pregnancy
|
||
Not yet recruiting |
NCT05890066 -
Single-port Versus Multi-port Laparoscopic Surgery for Ectopic Pregnancy
|
N/A | |
Completed |
NCT01855568 -
Methotrexate Treatment for Ectopic Pregnancy
|
Phase 3 | |
Not yet recruiting |
NCT04308343 -
The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy
|
N/A | |
Recruiting |
NCT06354439 -
Use of Letrozole for Ectopic Pregnancy
|
Phase 4 | |
Not yet recruiting |
NCT06300333 -
Treatment of Ectopic Pregnancy by Low Dose of Methotrexate
|
||
Completed |
NCT00194272 -
Two-Dose Methotrexate for Ectopic Pregnancy
|
Phase 3 | |
Enrolling by invitation |
NCT03579550 -
Hysteroscopic Metroplasty in Unexplained Infertile Women With Dysmorphic Uterus
|
N/A | |
Completed |
NCT05446012 -
Relationship Between Ectopic Pregnancy and Thyroid Disorders
|
||
Completed |
NCT00194168 -
Ectopic Pregnancy Biomarkers
|
N/A | |
Completed |
NCT02152696 -
Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location
|
Phase 3 | |
Not yet recruiting |
NCT04975984 -
Expectant Management of Ectopic Pregnancy
|